X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs FULFORD INDIA - Comparison Results

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA FULFORD INDIA ALEMBIC PHARMA/
FULFORD INDIA
 
P/E (TTM) x 19.1 398.8 4.8% View Chart
P/BV x 5.0 6.2 80.6% View Chart
Dividend Yield % 0.9 0.1 1,110.5%  

Financials

 ALEMBIC PHARMA   FULFORD INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
FULFORD INDIA
Mar-14
ALEMBIC PHARMA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs792942 84.0%   
Low Rs443450 98.4%   
Sales per share (Unadj.) Rs167.0691.4 24.2%  
Earnings per share (Unadj.) Rs38.211.5 333.0%  
Cash flow per share (Unadj.) Rs42.015.4 273.4%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.60.3 225.5%  
Book value per share (Unadj.) Rs84.9380.0 22.3%  
Shares outstanding (eoy) m188.523.90 4,833.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.71.0 367.2%   
Avg P/E ratio x16.260.7 26.6%  
P/CF ratio (eoy) x14.745.3 32.4%  
Price / Book Value ratio x7.31.8 397.0%  
Dividend payout %10.517.4 60.1%   
Avg Mkt Cap Rs m116,3832,714 4,287.6%   
No. of employees `000NA0.4 0.0%   
Total wages/salary Rs m4,214505 834.4%   
Avg. sales/employee Rs ThNM6,073.0-  
Avg. wages/employee Rs ThNM1,137.4-  
Avg. net profit/employee Rs ThNM100.7-  
INCOME DATA
Net Sales Rs m31,4872,696 1,167.7%  
Other income Rs m55125 43.9%   
Total revenues Rs m31,5422,822 1,117.8%   
Gross profit Rs m10,060-46 -21,680.6%  
Depreciation Rs m72215 4,750.7%   
Interest Rs m3710 387.4%   
Profit before tax Rs m9,35654 17,230.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,16010 22,502.1%   
Profit after tax Rs m7,19445 16,094.6%  
Gross profit margin %31.9-1.7 -1,856.6%  
Effective tax rate %23.117.7 130.6%   
Net profit margin %22.81.7 1,378.3%  
BALANCE SHEET DATA
Current assets Rs m15,0661,738 866.7%   
Current liabilities Rs m7,674545 1,408.9%   
Net working cap to sales %23.544.3 53.0%  
Current ratio x2.03.2 61.5%  
Inventory Days Days6748 138.2%  
Debtors Days Days414 943.8%  
Net fixed assets Rs m8,23712 69,222.3%   
Share capital Rs m37739 966.7%   
"Free" reserves Rs m15,4161,443 1,068.4%   
Net worth Rs m16,0051,482 1,080.0%   
Long term debt Rs m00-   
Total assets Rs m24,5942,077 1,184.3%  
Interest coverage x255.26.7 3,800.6%   
Debt to equity ratio x00-  
Sales to assets ratio x1.31.3 98.6%   
Return on assets %29.42.6 1,126.6%  
Return on equity %44.93.0 1,490.3%  
Return on capital %58.74.3 1,363.0%  
Exports to sales %55.70-   
Imports to sales %10.424.5 42.6%   
Exports (fob) Rs m17,551NA-   
Imports (cif) Rs m3,283659 498.0%   
Fx inflow Rs m17,81117 103,549.4%   
Fx outflow Rs m5,318673 790.0%   
Net fx Rs m12,493-656 -1,904.5%   
CASH FLOW
From Operations Rs m9,30490 10,337.7%  
From Investments Rs m-3,105105 -2,968.3%  
From Financial Activity Rs m-1,959-14 13,894.3%  
Net Cashflow Rs m4,240181 2,349.0%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.9 3.8 76.3%  
FIIs % 9.1 0.1 9,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 21.2 65.6%  
Shareholders   49,328 4,783 1,031.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  SANOFI INDIA  DR. DATSONS LABS  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 145 Points Up; Sun Pharma Rallies on Strong Earnings(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is flat while the Hang Seng is up 0.7%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


May 28, 2018 10:57 AM

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - SHASUN PHARMA COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS